Patents Examined by C Prasad
  • Patent number: 6331621
    Abstract: The invention involves nucleic acid molecules which encode activin like kinases, expression vectors, and cell lines.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: December 18, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Kohei Miyazono, Peter ten Dijke, Petra Franzen, Hidetoshi Yamashita, Carl-Henrik Heldin
  • Patent number: 6313272
    Abstract: A recombinant human IL-4 mutein numbered in accordance with wild-type IL-4 wherein the mutein comprises at least one amino acid substitution in the binding surface of either the A- or C-alpha helices of the wild-type IL-4 whereby the mutein binds to the IL-4R&agr; receptor with at least greater affinity than native IL-4. The substitution is more preferably selected from the group of positions consisting of, in the A-helix, positions 13 and 16, and in the C-helix, positions 81 and 89. A most preferred embodiment is the recombinant human IL-4 mutein wherein the substitution at position 13 is Thr to Asp. Pharmaceutical compositions, amino acid and polynucleotide sequences encoding the muteins, transformed host cells, antibodies to the muteins, and methods of treatment are also described.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: November 6, 2001
    Assignee: Bayer Corporation
    Inventors: Jeffrey M. Greve, Armen B. Shanafelt, Steven Roczniak
  • Patent number: 6271365
    Abstract: The invention involves three members of the activin like receptor kinase family, and the nucleic acids encoding these.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: August 7, 2001
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Kohei Miyazono, Peter ten Dijke, Petra Franzen, Hidetoshi Yamashita, Carl-Henrik Heldin